Tagamet HB TV ad claiming "full prescription strength" enjoined by district court.
This article was originally published in The Tan Sheet
Executive Summary
TAGAMET HB TV AD CLAIMING Rx STRENGTH HEARTBURN TREATMENT PROHIBITED by federal court Judge Harold Baer in an April 24 bench decision. The N.Y. Southern District Court judge determined that the SmithKline Beecham ad claims -- that Tagamet HB is the only approved OTC H2 antagonist available in "full prescription strength" and that "nothing stops stomach acid faster" -- are "misleading" and possibly claims of "literal falsity."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning